Key terms
About PEN
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PEN news
Apr 17
3:59am ET
RBC Capital Sticks to Their Buy Rating for Penumbra (PEN)
Apr 16
5:49am ET
3 Best Stocks to Buy Now, 4/16/2024, According to Top Analysts
Apr 15
7:36am ET
Penumbra price target raised to $265 from $264 at BTIG
Apr 12
8:29am ET
Piper Sandler Remains a Buy on Penumbra (PEN)
Apr 03
7:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 25
10:30pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 22
9:30am ET
Penumbra price target lowered to $280 from $290 at Truist
Mar 22
9:28am ET
Inari Medical price target lowered to $52 from $61 at Truist
Mar 19
6:16am ET
Positive Outlook for Penumbra: Accelerated THUNDER Trial Progress and Thunderbolt System Potential Justify Buy Rating
Mar 01
5:04am ET
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX)
Feb 25
11:35pm ET
Buy Rating Justified by Penumbra’s Market Presence and Projected Growth
Feb 23
9:47am ET
Penumbra falls -9.2%
Feb 23
9:25am ET
Penumbra price target lowered to $290 from $300 at Truist
Feb 23
8:31am ET
Penumbra price target lowered to $290 from $310 at Piper Sandler
Feb 23
7:51am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Penumbra (PEN), BioMarin Pharmaceutical (BMRN) and Insulet (PODD)
Feb 23
7:35am ET
Maintaining Buy Rating on Penumbra: Strong Growth Prospects and Strategic Focus
Feb 23
7:31am ET
Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN)
Feb 23
7:20am ET
RBC Capital Remains a Buy on Penumbra (PEN)
Feb 23
6:10am ET
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Penumbra (PEN) and BioMarin Pharmaceutical (BMRN)
Feb 23
5:45am ET
Hold Rating on Penumbra: Balancing Operational Strengths and Market Expectations
Feb 23
5:08am ET
Penumbra downgraded to Neutral from Overweight at JPMorgan
Feb 22
4:09pm ET
Penumbra sees FY24 revenue $1.23B-$1.27B, consensus $1.27B
Feb 22
4:07pm ET
Penumbra reports Q4 adjusted EPS 76c, consensus 70c
Feb 06
5:37am ET
Buy Rating Affirmed: Penumbra’s Strong Product Pipeline and Technological Advancements Set to Drive Growth
Jan 30
9:25pm ET
Truist Financial Remains a Buy on Penumbra (PEN)
Jan 26
5:36am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
No recent press releases are available for PEN
PEN Financials
Key terms
Ad Feedback
PEN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PEN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
